MXPA96005662A - Vacunas de papilomavirus. - Google Patents

Vacunas de papilomavirus.

Info

Publication number
MXPA96005662A
MXPA96005662A MXPA96005662A MX9605662A MXPA96005662A MX PA96005662 A MXPA96005662 A MX PA96005662A MX PA96005662 A MXPA96005662 A MX PA96005662A MX 9605662 A MX9605662 A MX 9605662A MX PA96005662 A MXPA96005662 A MX PA96005662A
Authority
MX
Mexico
Prior art keywords
papillomavirus
papillomavirus vaccines
proteins
recombinant
vaccines
Prior art date
Application number
MXPA96005662A
Other languages
English (en)
Inventor
C Cook James
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of MXPA96005662A publication Critical patent/MXPA96005662A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proveen vectores de expresion recombinantes que codifican las proteinas L1 y L2 de papilomavirus, metodos de fabricacion y uso de las proteinas recombinantes y particulas purificadas semejantes a virus constituidas de las proteinas recombinantes.
MXPA96005662A 1994-05-16 1995-05-15 Vacunas de papilomavirus. MXPA96005662A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24279494A 1994-05-16 1994-05-16
PCT/US1995/006006 WO1995031532A1 (en) 1994-05-16 1995-05-15 Papillomavirus vaccines

Publications (1)

Publication Number Publication Date
MXPA96005662A true MXPA96005662A (es) 2004-08-19

Family

ID=22916213

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA96005662A MXPA96005662A (es) 1994-05-16 1995-05-15 Vacunas de papilomavirus.

Country Status (24)

Country Link
EP (1) EP0757717B1 (es)
JP (1) JP3863559B2 (es)
CN (1) CN1152935A (es)
AT (1) ATE328068T1 (es)
AU (1) AU693203B2 (es)
BG (1) BG100974A (es)
BR (1) BR9507657A (es)
CA (1) CA2189882C (es)
CZ (1) CZ336696A3 (es)
DE (1) DE69535018T2 (es)
DK (1) DK0757717T3 (es)
ES (1) ES2264126T3 (es)
FI (1) FI119815B (es)
HU (1) HUT76354A (es)
MX (1) MXPA96005662A (es)
NO (1) NO322133B1 (es)
NZ (1) NZ285941A (es)
PL (1) PL183781B1 (es)
PT (1) PT757717E (es)
RO (1) RO117541B1 (es)
RU (1) RU2206608C2 (es)
SI (1) SI0757717T1 (es)
SK (1) SK147696A3 (es)
WO (1) WO1995031532A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
JPH10506014A (ja) * 1994-09-22 1998-06-16 メルク エンド カンパニー インコーポレーテッド ヒトパピローマウイルス６ａ型をコードするＤＮＡ
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
ATE324436T1 (de) * 1998-08-14 2006-05-15 Merck & Co Inc Verfahren zur reinigung von menschlichen, dem papillomavirus ähnlichen partikeln.
PL201482B1 (pl) 1998-10-16 2009-04-30 Smithkline Beecham Biolog Sposoby wytwarzania kompozycji szczepionki oraz kompozycja szczepionki
AUPP765398A0 (en) * 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
PT1150712E (pt) 1999-02-05 2008-12-22 Merck & Co Inc Formulações para a vacina do vírus do papiloma humano
DE10137102A1 (de) 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
ES2323454T5 (es) 2002-04-30 2012-11-14 Oncolytics Biotech Inc. Procedimiento mejorado de purificación de virus
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
MY140664A (en) * 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
KR101238798B1 (ko) 2004-09-30 2013-03-04 바이엘 헬스케어, 엘엘씨 생물학적 분자의 통합된 연속 제조를 위한 장치 및 방법
US7901921B2 (en) 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
SG10201502490YA (en) 2006-09-29 2015-05-28 Ligocyte Pharmaceuticals Inc Norovirus vaccine formulations
US8420103B2 (en) * 2007-01-30 2013-04-16 Transgene S.A. Papillomavirus vaccines
SG10201701988TA (en) 2007-03-14 2017-04-27 Ligocyte Pharmaceuticals Inc Virus like particle purification
MX2009014246A (es) * 2007-06-26 2010-03-31 Japan Health Science Found Antigeno de vacuna con la capacidad de inducir anticuerpo de neutralizacion y reaccion cruzada contra virus de papiloma humano del tipo de alto riesgo.
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
CN101918028B (zh) 2007-09-18 2015-01-07 莱戈赛特医药股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
RU2494106C2 (ru) * 2007-11-23 2013-09-27 Шанхай Зеран Биотекнолоджи Ко., Лтд. Гены, кодирующие главный капсидный белок l1 вируса папилломы человека, и их применение
EP3382011A1 (en) * 2008-08-08 2018-10-03 Takeda Vaccines, Inc. Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
PL2444103T3 (pl) * 2009-06-19 2018-05-30 Eyegene Inc. Szczepionka przeciwko rakowi szyjki macicy
CN102234661A (zh) * 2010-04-23 2011-11-09 北京生物制品研究所 人***瘤病毒类病毒颗粒的制备方法和外源蛋白表达盒、表达***
SG190418A1 (en) 2010-12-02 2013-07-31 Oncolytics Biotech Inc Liquid viral formulations
EA201390812A1 (ru) 2010-12-02 2013-11-29 Онколитикс Байотек Инк. Лиофилизированные вирусные составы
RU2445358C1 (ru) * 2011-02-15 2012-03-20 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантный штамм дрожжей pichia angusta - продуцент капсидного белка l1 вируса папилломы человека типа 18
RU2445357C1 (ru) * 2011-02-15 2012-03-20 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантный штамм дрожжей pichia angusta - продуцент капсидного белка l1 вируса папилломы человека типа 16
KR102151890B1 (ko) * 2011-04-29 2020-09-03 온콜리틱스 바이오테크 인코포레이티드 겔 침투 크로마토그래피를 이용한 바이러스의 정제방법
EP3299030B1 (en) 2011-07-11 2022-06-08 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations
CN103890177B (zh) * 2011-12-01 2016-03-09 开普敦大学 Hpv嵌合颗粒
CN109321592A (zh) * 2012-01-21 2019-02-12 北京安百胜生物科技有限公司 用汉逊酵母表达***产生hpv18 l1蛋白的方法
CN107916234A (zh) * 2012-03-28 2018-04-17 北京安百胜生物科技有限公司 用汉逊酵母表达***产生hpv6 l1蛋白的方法
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
CN110423774A (zh) * 2013-04-26 2019-11-08 北京安百胜生物科技有限公司 用汉逊酵母表达***产生hpv58 l1蛋白的方法
CN104120089B (zh) * 2013-04-26 2019-09-24 北京安百胜生物科技有限公司 用汉逊酵母表达***产生hpv52 l1蛋白的方法
CN110592133A (zh) * 2013-05-17 2019-12-20 北京安百胜生物科技有限公司 用汉逊酵母表达***产生hpv31 l1蛋白的方法
CN104673760B (zh) * 2013-11-29 2018-01-02 南京赛威信生物医药有限公司 一种原核细胞表达类病毒颗粒的纯化方法
RU2546242C1 (ru) * 2014-02-13 2015-04-10 Закрытое акционерное общество научно-производственная компания "Комбиотех" РЕКОМБИНАНТНЫЙ ШТАММ ДРОЖЖЕЙ Hansenula polymorpha - ПРОДУЦЕНТ ГЛАВНОГО КАПСИДНОГО БЕЛКА L1 ВИРУСА ПАПИЛЛОМЫ ЧЕЛОВЕКА ТИПА 18
RU2546241C1 (ru) * 2014-02-13 2015-04-10 Закрытое акционерное общество научно-производственная компания "Комбиотех" РЕКОМБИНАНТНЫЙ ШТАММ ДРОЖЖЕЙ Hansenula polymorpha - ПРОДУЦЕНТ ГЛАВНОГО КАПСИДНОГО БЕЛКА L1 ВИРУСА ПАПИЛЛОМЫ ЧЕЛОВЕКА ТИПА 16
RU2546243C1 (ru) * 2014-02-13 2015-04-10 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантная вакцина для профилактики папилломавирусной инфекции человека и способ ее получения
RU2546240C1 (ru) * 2014-02-13 2015-04-10 Закрытое акционерное общество научно-производственная компания "Комбиотех" РЕКОМБИНАНТНЫЙ ШТАММ ДРОЖЖЕЙ Hansenula polymorpha - ПРОДУЦЕНТ ГЛАВНОГО КАПСИДНОГО БЕЛКА L1 ВИРУСА ПАПИЛЛОМЫ ЧЕЛОВЕКА ТИПА 56
KR101825996B1 (ko) * 2014-12-26 2018-02-09 아이진 주식회사 인유두종 바이러스의 바이러스 유사 입자 제조방법
BR112018004400A2 (pt) * 2015-09-04 2018-12-04 Inventprise Llc composições de vacina vlp estabilizadas
RU2676160C1 (ru) * 2018-02-14 2018-12-26 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантный штамм дрожжей Hansenula polymorpha - продуцент главного капсидного белка L1 вируса папилломы человека типа 11
RU2681174C1 (ru) * 2018-07-12 2019-03-04 Закрытое акционерное общество научно-производственная компания "Комбиотех" Способ получения рекомбинантной вакцины для профилактики папилломавирусной инфекции человека, рекомбинантная вакцина
CN116426396B (zh) * 2023-06-09 2023-09-01 内蒙古工业大学 一株耐硫酸铵酿酒酵母及其筛选方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2586428B1 (fr) * 1985-08-26 1988-11-25 Pasteur Institut Polypeptides et anticorps, caracteristiques du papillomavirus et leurs applications au diagnostic in vitro, a la prevention et/ou la lutte contre des infections a papillomavirus
DE3625257A1 (de) * 1986-07-23 1988-02-04 Behringwerke Ag Expressionsprodukte der menschlichen papillomviren typ 16 und 18, fuer diese proteine spezifische antikoerper und diese antikoerper bzw. entsprechende dna enthaltende diagnostika
DE122007000019I1 (de) * 1991-07-19 2007-07-26 Univ Queensland Impfstoffen gegen Papillomavirus
WO1994000152A1 (en) * 1992-06-25 1994-01-06 Georgetown University Papillomavirus vaccines
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
DE4332596A1 (de) * 1993-09-24 1995-03-30 Martin Josef Dr Sapp Monoklonale Antikörper
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product

Also Published As

Publication number Publication date
EP0757717A4 (en) 1998-04-15
NO964862D0 (no) 1996-11-15
DE69535018D1 (de) 2006-07-06
AU2549595A (en) 1995-12-05
AU693203B2 (en) 1998-06-25
WO1995031532A1 (en) 1995-11-23
ATE328068T1 (de) 2006-06-15
JPH10500847A (ja) 1998-01-27
EP0757717B1 (en) 2006-05-31
RO117541B1 (ro) 2002-04-30
JP3863559B2 (ja) 2006-12-27
DE69535018T2 (de) 2007-02-15
BG100974A (en) 1998-04-30
CA2189882A1 (en) 1995-11-23
FI119815B (fi) 2009-03-31
HUT76354A (en) 1997-08-28
EP0757717A1 (en) 1997-02-12
ES2264126T3 (es) 2006-12-16
DK0757717T3 (da) 2006-09-25
CZ336696A3 (en) 1997-07-16
PL183781B1 (pl) 2002-07-31
NO322133B1 (no) 2006-08-21
PT757717E (pt) 2006-09-29
HU9603155D0 (en) 1997-01-28
NO964862L (no) 1997-01-16
PL317234A1 (en) 1997-03-17
FI964592A0 (fi) 1996-11-15
FI964592A (fi) 1996-11-15
SK147696A3 (en) 1997-08-06
SI0757717T1 (sl) 2006-08-31
CA2189882C (en) 2005-09-20
CN1152935A (zh) 1997-06-25
BR9507657A (pt) 1997-09-09
RU2206608C2 (ru) 2003-06-20
NZ285941A (en) 1998-05-27

Similar Documents

Publication Publication Date Title
HU9603155D0 (en) Papillomavirus vaccines
CZ63995A3 (en) Virus vectors and their use in gene therapy
WO2001034801A3 (en) Recombinant gelatin in vaccines
NZ503830A (en) Papilloma virus capsomere vaccine formulations and methods of use
GEP20084431B (en) Papilloma virus vaccine
IL130964A0 (en) Practical in vitro sialylation of recombinant glycoproteins
EP0762894A4 (en) METHOD FOR INDUCING IMMUNE REACTION USING A VENEZUELA EQUINE ENCEPHALITE VIVUS EXPRESSING A HETEROLOGOUS IMMUNOGENE
MY150893A (en) Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
AU7237391A (en) Carrier-bound recombinant protein, process for producing it and its use as an immunogen and vaccine
MX9708426A (es) Polipeptido hk2 de variante estable.
UA35639C2 (uk) Спосіб одержання композиції очищеного капсидного білка вірусу папіломи людини
IL117459A (en) Dna encoding human papillomavirus type 18
AU8200791A (en) Ehv-4 glycoprotein vaccine
EP0957936A4 (en) RECOMBINANT PAPILLONAVIRUS VACCINE FORMULATIONS
WO2004089973A3 (en) Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
HUP0003511A2 (hu) Hepatitisz-B-vírus polipeptidek
AU1814792A (en) Immunogenic peptides or polypeptides of the bvd virus and related viruses, vaccines incorporating them or expressing them, methods and means of production thereof
AU1209797A (en) Novel antigenic proteins of mycoplasmata, genes thereof, and recombinant vector and use of the same

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status
GB Transfer or rights
HC Change of company name or juridical status